{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:34:42Z","timestamp":1791023682362,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T00:00:00Z","timestamp":1258416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T00:00:00Z","timestamp":1258416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s00198-009-1097-5","type":"journal-article","created":{"date-parts":[[2009,11,16]],"date-time":"2009-11-16T15:11:36Z","timestamp":1258384296000},"page":"723-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity"],"prefix":"10.1007","volume":"21","author":[{"given":"P.","family":"Musette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,17]]},"reference":[{"key":"1097_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u201359","journal-title":"Lancet"},{"key":"1097_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1398-9995.1997.tb01017.x","volume":"52","author":"T Hunziker","year":"1997","unstructured":"Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R (1997) Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 52:388\u201393","journal-title":"Allergy"},{"key":"1097_CR3","first-page":"765","volume":"137","author":"M Bigby","year":"2001","unstructured":"Bigby M (2001) Rates of cutaneous reactions to drugs. Arch Dermatol 137:765\u201370","journal-title":"Arch Dermatol"},{"key":"1097_CR4","unstructured":"US Food and Drugs Administration (2009) Pharmapendium"},{"key":"1097_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","volume":"5","author":"ER Gomes","year":"2005","unstructured":"Gomes ER, Demoly P (2005) Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 5:309\u201316","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1097_CR6","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102:4134\u201339","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1097_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"WH Chung","year":"2004","unstructured":"Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT (2004) Medical genetics: a marker for Stevens Johnson syndrome. Nature 428:486","journal-title":"Nature"},{"key":"1097_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568\u201379","journal-title":"N Engl J Med"},{"key":"1097_CR9","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M (2007) Epidemiology and causes of severe cutaneous adverse reactions to drugs, pp 18\u201331","DOI":"10.1159\/000104186"},{"key":"1097_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/archderm.145.1.67","volume":"145","author":"M Eshki","year":"2009","unstructured":"Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, Chosidow O, Guillot I, Paradis V, Joly P, Crickx B, Ranger-Rogez S, Descamps V (2009) Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 145:67\u201372","journal-title":"Arch Dermatol"},{"key":"1097_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","volume":"209","author":"JC Roujeau","year":"2005","unstructured":"Roujeau JC (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209:123\u201329","journal-title":"Toxicology"},{"key":"1097_CR12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0031-6997(24)01501-1","volume":"53","author":"CK Svensson","year":"2001","unstructured":"Svensson CK, Cowen EW, Gaspari AA (2001) Cutaneous drug reactions. Pharmacol Rev 53:357\u201379","journal-title":"Pharmacol Rev"},{"key":"1097_CR13","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/j.ddmec.2008.09.009","volume":"5","author":"W Aberer","year":"2008","unstructured":"Aberer W, Kranke B (2008) Clinical manifestations and mechanisms of skin reactions after systemic drug administration. Drug Discovery Today 5:e237\u2013e247","journal-title":"Drug Discovery Today"},{"key":"1097_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2165\/00002018-200730110-00003","volume":"30","author":"L Valeyrie-Allanore","year":"2007","unstructured":"Valeyrie-Allanore L, Sassolas B, Roujeau JC (2007) Drug-induced skin, nail and hair disorders. Drug Saf 30:1011\u201330","journal-title":"Drug Saf"},{"key":"1097_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMcp022558","volume":"350","author":"WL Morison","year":"2004","unstructured":"Morison WL (2004) Clinical practice. Photosensitivity. N Engl J Med 350:1111\u201317","journal-title":"N Engl J Med"},{"key":"1097_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clindermatol.2004.06.012","volume":"23","author":"R Wolf","year":"2005","unstructured":"Wolf R, Orion E, Marcos B, Matz H (2005) Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23:171\u201381","journal-title":"Clin Dermatol"},{"key":"1097_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","volume":"15","author":"H Bocquet","year":"1996","unstructured":"Bocquet H, Bagot M, Roujeau JC (1996) Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 15:250\u2013257","journal-title":"Semin Cutan Med Surg"},{"key":"1097_CR18","doi-asserted-by":"crossref","unstructured":"Shiohara T, Takahashi R, Kano Y (2007) Drug-induced hypersensitivity syndrome and viral reactivation, pp. 251-266","DOI":"10.1159\/000104205"},{"key":"1097_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.autrev.2008.06.004","volume":"7","author":"AT Borchers","year":"2008","unstructured":"Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 7:598\u2013605","journal-title":"Autoimmun Rev"},{"key":"1097_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","volume":"128","author":"M Mockenhaupt","year":"2008","unstructured":"Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128:35\u201344","journal-title":"J Invest Dermatol"},{"key":"1097_CR21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","volume":"8","author":"PD Ghislain","year":"2002","unstructured":"Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8:5","journal-title":"Dermatol Online J"},{"key":"1097_CR22","doi-asserted-by":"crossref","unstructured":"Allanore L, Roujeau JC (2007) Clinic and pathogenesis of severe bullous skin reactions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, pp. 267\u2013277","DOI":"10.1159\/000104206"},{"key":"1097_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2332\/allergolint.55.1","volume":"55","author":"T Shiohara","year":"2006","unstructured":"Shiohara T, Inaoka M, Kano Y (2006) Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 55:1\u20138","journal-title":"Allergol Int"},{"key":"1097_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490\u2013493","journal-title":"Science"},{"key":"1097_CR25","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","volume":"65","author":"O Faye","year":"2005","unstructured":"Faye O, Roujeau JC (2005) Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 65:2085\u201390","journal-title":"Drugs"},{"key":"1097_CR26","unstructured":"European Medicines Agency (2008) Alendronate. Summary of product characteristics"},{"key":"1097_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1034\/j.1600-0536.2003.480212_2.x","volume":"48","author":"M Kimura","year":"2003","unstructured":"Kimura M, Kawada A, Murayama Y, Murayama M (2003) Drug eruption due to alendronate sodium hydrate. Contact Dermatitis 48:116","journal-title":"Contact Dermatitis"},{"key":"1097_CR28","first-page":"398","volume":"80","author":"P Kontoleon","year":"2000","unstructured":"Kontoleon P, Ilias I, Stavropoulos PG, Papapetrou PD (2000) Urticaria after administration of alendronate. Acta Derm Venereol 80:398","journal-title":"Acta Derm Venereol"},{"key":"1097_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","volume":"14","author":"PN Biswas","year":"2003","unstructured":"Biswas PN, Wilton LV, Shakir SA (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507\u201314","journal-title":"Osteoporos Int"},{"key":"1097_CR30","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1067\/mjd.2003.245","volume":"48","author":"WA High","year":"2003","unstructured":"High WA, Cohen JB, Wetherington W, Cockerell CJ (2003) Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. J Am Acad Dermatol 48:945\u201346","journal-title":"J Am Acad Dermatol"},{"key":"1097_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1600-0536.2006.01071.x","volume":"57","author":"T Brinkmeier","year":"2007","unstructured":"Brinkmeier T, Kugler K, Lepoittevin JP, Frosch PJ (2007) Adverse cutaneous drug reaction to alendronate. Contact Dermatitis 57:123\u201325","journal-title":"Contact Dermatitis"},{"key":"1097_CR32","first-page":"389","volume":"4","author":"A Lazarov","year":"2002","unstructured":"Lazarov A, Moss K, Plosk N, Cordoba M, Baitelman L (2002) Alendronate-induced lichen planus. Isr Med Assoc J 4:389\u201390","journal-title":"Isr Med Assoc J"},{"key":"1097_CR33","unstructured":"US Food and Drugs Administration (2002) Risedronate. Description"},{"key":"1097_CR34","unstructured":"(2009) Vidal 2009. Le Dictionnaire, 85th ed"},{"key":"1097_CR35","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00198-005-1986-1","volume":"16","author":"BA Barrera","year":"2005","unstructured":"Barrera BA, Wilton L, Harris S, Shakir SA (2005) Prescription-event monitoring study on 13, 164 patients prescribed risedronate in primary care in England. Osteoporos Int 16:1989\u201398","journal-title":"Osteoporos Int"},{"key":"1097_CR36","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1398-9995.2008.01836.x","volume":"63","author":"H Belhadjali","year":"2008","unstructured":"Belhadjali H, Slim R, Aouam K, Youssef M, Zili J (2008) Cutaneous vasculitis induced by risedronate. Allergy 63:1405","journal-title":"Allergy"},{"key":"1097_CR37","unstructured":"European Medicines Agency (2007) Ibandronate. Summary of product characteristics"},{"key":"1097_CR38","unstructured":"European Medicines Agency (2008) Zoledronic acid. Summary of product characteristics"},{"key":"1097_CR39","first-page":"455","volume":"24","author":"EC Rizos","year":"2006","unstructured":"Rizos EC, Milionis HJ, Elisaf MS (2006) Fever with rash following zolendronic acid administration. Clin Exp Rheumatol 24:455","journal-title":"Clin Exp Rheumatol"},{"key":"1097_CR40","unstructured":"European Medicines Agency (2008) Strontium ranelate. Summary of product characteristics"},{"key":"1097_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/archdermatol.2007.54","volume":"144","author":"C Groves","year":"2008","unstructured":"Groves C (2008) Interstitial granulomatous reaction to strontium ranelate. Arch Dermatol 144:268\u201369","journal-title":"Arch Dermatol"},{"key":"1097_CR42","doi-asserted-by":"crossref","unstructured":"Boada A, Carrascosa J, Leal L, Ferrandiz C (2009) Generalized cutaneous drug eruption due to strontium ranelate. J Eur Acad Dermatol Venereol 0 (in press)","DOI":"10.1111\/j.1468-3083.2008.02856.x"},{"key":"1097_CR43","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00198-008-0734-8","volume":"19","author":"I Pernicova","year":"2008","unstructured":"Pernicova I, Middleton ET, Aye M (2008) Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int 19:1811\u201312","journal-title":"Osteoporos Int"},{"key":"1097_CR44","doi-asserted-by":"crossref","unstructured":"Jonville-Bera AP, Crickx B, Aaron L, Hartingh I, utret-Leca E (2009) Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy","DOI":"10.1111\/j.1398-9995.2009.01940.x"},{"key":"1097_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00198-008-0677-0","volume":"20","author":"HY Lee","year":"2009","unstructured":"Lee HY, Lie D, Lim KS, Thirumoorthy T, Pang SM (2009) Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 20:161\u201362","journal-title":"Osteoporos Int"},{"key":"1097_CR46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.2008.03273.x","volume":"66","author":"A Grosso","year":"2008","unstructured":"Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L (2008) Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66:689\u201394","journal-title":"Br J Clin Pharmacol"},{"key":"1097_CR47","unstructured":"European Medicines Agency (2008) Raloxifene. Summary of product characteristics"},{"key":"1097_CR48","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00198-004-1710-6","volume":"16","author":"D Layton","year":"2005","unstructured":"Layton D, Clarke A, Wilton LV, Shakir SA (2005) Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study. Osteoporos Int 16:490\u2013500","journal-title":"Osteoporos Int"},{"key":"1097_CR49","unstructured":"European Medicines Agency (2008) Teriparatide. Summary of product characteristics"},{"key":"1097_CR50","unstructured":"European Medicines Agency (2007) Parathyroid hormone. Summary of product characteristics"},{"key":"1097_CR51","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/ncpendmet0981","volume":"4","author":"SA Burnett-Bowie","year":"2008","unstructured":"Burnett-Bowie SA (2008) Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture? Nat Clin Pract Endocrinol Metab 4:660\u2013661","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1097_CR52","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u201331","journal-title":"N Engl J Med"},{"key":"1097_CR53","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878\u201382","journal-title":"Lancet"},{"key":"1097_CR54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u201321","journal-title":"JAMA"},{"key":"1097_CR55","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4065\/84.3.268","volume":"84","author":"B Schnyder","year":"2009","unstructured":"Schnyder B, Pichler WJ (2009) Mechanisms of drug-induced allergy. Mayo Clin Proc 84:268\u201372","journal-title":"Mayo Clin Proc"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-009-1097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-009-1097-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-009-1097-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-009-1097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T07:48:22Z","timestamp":1739432902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-009-1097-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,17]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1007\/s00198-009-1097-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,17]]},"assertion":[{"value":"28 July 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}